Case: 19-15074, 07/17/2020, ID: 11757550, DktEntry: 118, Page 1 of 2

## LAW OFFICES

## WILLIAMS & CONNOLLY LLP

725 TWELFTH STREET, N.W.

CRAIG D. SINGER (202) 434-5964 csinger@wc.com WASHINGTON, D. C. 20005-5901 (202) 434-5000 FAX (202) 434-5029

EDWARD BENNETT WILLIAMS (1920-1988)
PAUL R. CONNOLLY (1922-1978)

July 17, 2020

## Via CM/ECF

Molly C. Dwyer, Clerk of Court United States Court of Appeals for the Ninth Circuit P.O. Box 193939 San Francisco, CA 94119-3939

> Re: John Doe, et al. v. CVS Pharmacy, Inc., et al., No. 19-15074 Oral argument held June 12, 2020

Dear Ms. Dwyer:

Decisions have issued in the cases for which the Court's June 16 order deferred submission of this appeal: *Schmitt v. Kaiser Foundation Health Plan*, No. 18-35846, 2020 WL 3969281 (9th Cir. 2020) ("*Schmitt*"), and *E.S. v. Regence Blueshield*, No. 18-35892, 2020 WL 3969675 (9th Cir. 2020).

Schmitt (which E.S. incorporates) declined to decide the legal issues presented in this appeal concerning disparate-impact claims under the ACA (§ 1557) and the Rehabilitation Act (§ 504) because the plaintiffs alleged only intentional discrimination: defendants excluded coverage for hearing treatments purposefully to target the hearing disabled. Schmitt at \*5 ("Schmitt . . . did not allege a disparate impact claim"), \*6, \*10. Here, by contrast, Appellants assert a disparate impact on HIV/AIDS patients incidental to the Program for all specialty drugs. See, e.g., CVS Br. 16–17 & n.6.

Schmitt declined to decide the open question in this Circuit whether disparate-impact claims like Appellants' are available under § 504, and its reasoning casts significant doubt that they are permitted after Alexander v. Sandoval, 532 U.S. 275 (2001). Schmitt at \*5, \*6; cf. Doe v. BCBS of Tenn., Inc., 926 F.3d 235, 242 (6th Cir. 2019) (concluding § 504 does not recognize disparate-impact claims); CVS Br. 17–22.

Schmitt also declined to decide whether § 1557 permits disability discrimination claims beyond those available through § 504. *Id.* at \*5. Operative agency guidance, which recently superseded the commentary consulted (and discounted) in *Schmitt*, *id.*, answers this question in the negative. *See* June 5 and 16, 2020 Rule 28(j) Letters, Dkt. Nos. 111.1 & 117.

Case: 19-15074, 07/17/2020, ID: 11757550, DktEntry: 118, Page 2 of 2

## WILLIAMS & CONNOLLY LLP

July 17, 2020 Page 2

Schmitt concluded only that the ACA permits at least some *intentional*-discrimination claims for plan designs targeting the disabled, relying on regulations, not applicable here, governing "individual[] and small employer" plans. *Compare Schmitt* at \*2, \*6, *with* EOR 159–60; EOR 21–22 ¶¶ 15–17; CVS Br. 52–53. Ultimately, *Schmitt* and *E.S.* affirmed dismissal of the plaintiffs' complaints for failure to adequately plead intentional discrimination ("proxy" or otherwise) and remanded for leave to amend. *Schmitt* at \*10–11.

Respectfully submitted,

Craig D. Singer

Counsel for Appellees CVS Pharmacy, Inc., Caremark, L.L.C., and Caremark California Specialty Pharmacy, L.L.C.